Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · IEX Real-Time Price · USD
1.700
+0.020 (1.19%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Ikena Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | TTM | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 3.85 | 9.16 | 15.62 | 30.99 | 9.19 | 13.75 | Upgrade
|
| Revenue Growth (YoY) | -78.08% | -41.35% | -49.59% | 237.01% | -33.15% | 1289.19% | Upgrade
|
| Cost of Revenue | 53.75 | 59.65 | 64.32 | 47.11 | 44.85 | 24.94 | Upgrade
|
| Gross Profit | -49.9 | -50.49 | -48.7 | -16.12 | -35.65 | -11.19 | Upgrade
|
| Selling, General & Admin | 25.65 | 24.93 | 22.2 | 18.02 | 8.87 | 7.31 | Upgrade
|
| Operating Expenses | 25.65 | 24.93 | 22.2 | 18.02 | 8.87 | 7.31 | Upgrade
|
| Operating Income | -75.55 | -75.42 | -70.9 | -34.14 | -44.52 | -18.49 | Upgrade
|
| Interest & Investment Income | 7.93 | 7.11 | 2.15 | 0.02 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.03 | -0.02 | -0.01 | - | 0.26 | 1.68 | Upgrade
|
| EBT Excluding Unusual Items | -67.65 | - | - | - | - | - | Upgrade
|
| Merger & Restructuring Charges | -2.58 | - | - | - | - | - | Upgrade
|
| Pretax Income | -70.23 | -68.33 | -68.77 | -34.12 | -44.26 | -16.82 | Upgrade
|
| Income Tax Expense | -0.14 | -0.16 | - | - | - | - | Upgrade
|
| Net Income | -70.09 | -68.17 | -68.77 | -34.12 | -44.26 | -16.82 | Upgrade
|
| Net Income to Common | -70.09 | -68.17 | -68.77 | -34.12 | -44.26 | -16.82 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 42 | 36 | 28 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 42 | 36 | 28 | 3 | 3 | Upgrade
|
| Shares Change (YoY) | 23.46% | 15.33% | 29.32% | 911.88% | 4.43% | 55.37% | Upgrade
|
| EPS (Basic) | -1.57 | -1.63 | -1.90 | -1.22 | -16.00 | -6.35 | Upgrade
|
| EPS (Diluted) | -1.57 | -1.63 | -1.90 | -1.22 | -16.00 | -6.35 | Upgrade
|
| Free Cash Flow | -78.53 | -80.16 | -75.54 | -62.01 | -38.59 | 47.61 | Upgrade
|
| Free Cash Flow Per Share | -1.76 | -1.92 | -2.09 | -2.22 | -13.95 | 17.98 | Upgrade
|
| Gross Margin | - | - | - | -52.03% | - | -81.33% | Upgrade
|
| Operating Margin | -1963.76% | -823.33% | -453.99% | -110.18% | -484.22% | -134.46% | Upgrade
|
| Profit Margin | - | - | - | -110.10% | - | -122.28% | Upgrade
|
| Free Cash Flow Margin | -2041.20% | -875.08% | -483.67% | -200.14% | -419.75% | 346.19% | Upgrade
|
| EBITDA | -74.54 | -74.4 | -70.15 | -33.59 | -44.22 | -18.25 | Upgrade
|
| EBITDA Margin | - | - | - | -108.42% | - | -132.69% | Upgrade
|
| D&A For EBITDA | 1.01 | 1.02 | 0.75 | 0.54 | 0.3 | 0.24 | Upgrade
|
| EBIT | -75.55 | -75.42 | -70.9 | -34.14 | -44.52 | -18.49 | Upgrade
|
| EBIT Margin | - | - | - | -110.18% | - | -134.46% | Upgrade
|
Source: S&P Capital IQ. Standard template.